Fig. 5
Activation of Wnt signalling increased excitatory and inhibitory synaptic transmission in the hippocampus. a–d Recordings of postsynaptic currents of CA1 pyramidal neurons from acute brain slices of the vehicle and AMBMP-treatment groups. Representative traces (up) and cumulative distribution plots and bar graphs showed the amplitude (left) and frequency (right) of sEPSCs, and sIPSCs. a, c Recorded one hour after one treatment regimen with AMBMP (i.p. 5mg/kg). b, d Recorded one day after the 3-day treatment regimen of AMBMP (i.p. one dose of 5mg/kg AMBMP per day for 3 continuous days). For all comparisons, n=8 neurons from 3 rats/group. e Relative expression of β-catenin and sFRP1 on hippocampus from one treatment and 3-day treatment regimens. f, g Relative expression of the γ2, δ, and α5 subunits of GABAARs in total and membrane hippocampal protein level in two treatment regimens. All the expression of the protein was standardized by the vehicle group of each treatment. h, i Relative expression of p-GluA1(Ser845), GluA1, and PSD95 in the hippocampus in two treatment regimens. An unpaired t-test was performed to assess the expression differences between the vehicle and AMBMP-administrated groups. Data represent means ± SEM. *p<0.05, **p<0.005, ***p<0.001, &p=0.07 j The expression of p-GluA1 (Ser845)/GluA1 ratio in two treatment regimens. Unpaired t-test test was performed in comparison of once-AMBMP versus the 3D-AMBMP group. The data were normalized to the vehicle group of each regimen. Data represent means ± SEM. #p=0.06. 1once-AMBMP: sampled one hour after one treatment (i.p. AMBMP, 5mg/kg). 23D-AMBMP: sampled one day after 3-day treatment (i.p. AMBMP, 5mg/kg per day for 3 continuous days)